Mikael Dolsten - 07 Nov 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role: President R&D
Signature: Susan E. Grant, by power of atty., for Mikael Dolsten
Issuer symbol: PFE
Transactions as of: 07 Nov 2022
Transactions value $: $2,627,260
Form type: 4
Filing time: 09 Nov 2022, 15:08:54 UTC
Previous filing: 12 May 2022
Next filing: 24 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PFE	Common Stock	Options Exercise	$1,536,799	+50,938	+14.94%	$30.17	391,837	07 Nov 2022	Direct	F1
transaction	PFE	Common Stock	Options Exercise	$1,090,460	+28,170	+7.19%	$38.71	420,007	07 Nov 2022	Direct	F1
holding	PFE	Common Stock						1,848	07 Nov 2022	By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-127,146	-100%	$0^*	0	07 Nov 2022	Common Stock	127,146	$30.17	Direct
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-133,430	-100%	$0^*	0	07 Nov 2022	Common Stock	133,430	$38.71	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $45.07)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.

Content

Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $45.07)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.